Colliers Securities analyst Eugene Mannheimer reiterated a Buy rating on NextGen Healthcare (NASDAQ:NXGN) Inc on Thursday, setting a price target of $25, which is approximately 31.58% above the present share price of $19.
Mannheimer expects NextGen Healthcare Inc to post earnings per share (EPS) of $0.01 for the first quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in NextGen Healthcare, with an average price target of $21.5.
The analysts price targets range from a high of $25 to a low of $18.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $141.75 million and a net profit of $3.15 million. The company's market cap is $1.27 billion.
According to TipRanks.com, Colliers Securities analyst Eugene Mannheimer is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 16.1% and a 60.26% success rate.
NextGen Healthcare, Inc. engages in the development and marketing of electronic health records, practice management, revenue cycle management, and interoperability solutions. It offers the core; automation and workflow; analytics, population health, and patient engagement, interoperability; managed services; professional services; and client service and support. The company was founded by Sheldon Razin in 1974 and is headquartered in Irvine, CA.